No.

Publication Date

Citing Article

1

2024

Eric Jou, 2024; 209: 1.  https://doi.org/10.1016/bs.pmbts.2024.03.036

2

2024

Eric Jou, Natasha Chaudhury, Fizza Nasim. Novel therapeutic strategies targeting myeloid-derived suppressor cell immunosuppressive mechanisms for cancer treatment, Exploration of Targeted Anti-tumor Therapy. 2024; 5: 187.  https://doi.org/10.37349/etat.2024.00212

3

2024

Sunanda Rajkumari, Jaspreet Singh, Usha Agrawal, Sandeep Agrawal. Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives, International Immunopharmacology. 2024; 142: 112949112949.  https://doi.org/10.1016/j.intimp.2024.112949

4

2026

Wei R. Tan, David A. Long, Luigi Gnudi. Neurite outgrowth inhibitor-B in physiology and disease, Physiological Reviews. 2026; 106: 239.  https://doi.org/10.1152/physrev.00052.2024

5

2024

James Michael Verner, Harry Frederick Arbuthnott, Raghavskandhan Ramachandran, Manini Bharadwaj, Natasha Chaudhury, Eric Jou. Emerging roles of type 1 innate lymphoid cells in tumour pathogenesis and cancer immunotherapy, Exploration of Targeted Anti-tumor Therapy. 2024; 5: 296.  https://doi.org/10.37349/etat.2024.00219

6

2025

Annamaria Colacci, Emanuela Corsini, Miriam Naomi Jacobs. Addressing Immune Response Dysfunction in an Integrated Approach for Testing and Assessment for Non-Genotoxic Carcinogens in Humans: A Targeted Analysis, International Journal of Molecular Sciences. 2025; 26: 6310.  https://doi.org/10.3390/ijms26136310

7

2025

S. Hone Lopez, S. Loipfinger, A. Bhattacharya, M. Jalving, S. F. Oosting, T. J. N. Hiltermann, M. de Bruyn, E. G. E. de Vries, J. J. de Haan, R. S. N. Fehrmann. Upfront whole blood transcriptional patterns in patients receiving immune checkpoint inhibitors associate with clinical outcome, Cancer Immunology, Immunotherapy. 2025; 74: 301.  https://doi.org/10.1007/s00262-025-04155-4

8

2024

Hesam Abouali, Michelle Przedborski, Mohammad Kohandel, Mahla Poudineh. Investigating nano-sized tumor-derived extracellular vesicles in enhancing anti-PD-1 immunotherapy, Nanoscale. 2024; 16: 19062.  https://doi.org/10.1039/D4NR00729H

9

2024

Milad Taghizadeh Anvar, Kimiya Rashidan, Nima Arsam, Ashkan Rasouli-Saravani, Hamidreza Yadegari, Ali Ahmadi, Zeynab Asgari, Ahmad Ghorbani Vanan, Farid Ghorbaninezhad, Safa Tahmasebi. Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies?, Cancer Cell International. 2024; 24: 355.  https://doi.org/10.1186/s12935-024-03525-9

10

2024

Julia Meidenbauer, Matthias Wachter, Sebastian R. Schulz, Nada Mostafa, Lilli Zülch, Benjamin Frey, Rainer Fietkau, Udo S. Gaipl, Tina Jost. Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC, Frontiers in Oncology. 2024; 14: 1460150.  https://doi.org/10.3389/fonc.2024.1460150

11

2024

Ludovica Lopresti, Vanessa Tatangelo, Cosima T. Baldari, Laura Patrussi. Rewiring the T cell-suppressive cytokine landscape of the tumor microenvironment: a new frontier for precision anti-cancer therapy, Frontiers in Immunology. 2024; 15: 1418527.  https://doi.org/10.3389/fimmu.2024.1418527

12

2024

James Michael Verner, Harry Frederick Arbuthnott, Raghavskandhan Ramachandran, Manini Bharadwaj, Natasha Chaudhury, Eric Jou. Emerging roles of type 1 innate lymphoid cells in tumour pathogenesis and cancer immunotherapy, Exploration of Targeted Anti-tumor Therapy. 2024; 5: 296.  https://doi.org/10.37349/etat.2024.00219

13

2025

Sumon Mukherjee, Ahana Ghosh, Sourio Chakraborty, Udit Basak, Sumoyee Mukherjee, Tanya Das, Gaurisankar Sa. Tumor-infiltrating lymphocytes and tumor-associated macrophages in cancer immunoediting: a targetable therapeutic axis, Frontiers in Immunology. 2025; 16: 1655176.  https://doi.org/10.3389/fimmu.2025.1655176